




Healthcare Industry News: degenerative disc disease
News Release - December 20, 2007
SpineOvations to Acquire Discogen Technology
SAN DIEGO--(HSMN NewsFeed)--SpineOvations, a San Diego-based medical technology company focused on the development of new and innovative products, announced today that it has entered into an agreement to acquire core technology from Discogen, an emerging medical device organization based in Weston, Florida specializing in the development of technologies to treat early disc degeneration.“Combining SpineOvation’s resources and technology with Discogen’s core technology makes natural sense,” said SpineOvations CEO, M. Ross Simmonds. “Discogen’s technology provides a method for intradiscal drug delivery which could dramatically enhance treatment for those suffering from early stage degenerative disc disease. We believe this to be a perfect complement to our DiscSeal™ technology and our overall strategic goal to develop solutions for chronic back pain as a result of internal disc derangement (IDD).”
Simmonds added that Discogen’s platform technology concept also provides a method for alleviating symptoms of a degenerative disc disease in a subject by delivering appropriate amounts of drug compounds into the disc subject to degenerative disc disease.
“I’m very excited about this opportunity to bring our technology and expertise to SpineOvations,” said Peter Zahos, MD, founder and CEO of Discogen and Chairman of the Department of Neurosurgery at the Cleveland Clinic, Florida. “The strategic vision of both organizations is in sync and hopefully with time we will be able to expand beyond what we are developing now and address a full spectrum of disc degeneration issues with varying approaches for each level of degeneration severity.”
SpineOvations is focused on the development of biocompatible injectables for the stabilization of spinal disc integrity and for other orthopedic applications, including non-surgical connective tissue repair. The company’s technology platform consists of a novel, non-surgical application for identifying and treating spinal disc tears or fissures to seal and stabilize the structural integrity of the spinal disc.
SpineOvation’s new treatment concept integrates the use of discography with the administration of the company’s DiscSeal™, an injectable agent for soft tissue engineering, designed to fill and seal the disc defect and provide internal disc stabilization and pain relief for the millions of patients with chronic back pain as a result of internal disc derangement (IDD). This innovative approach offers the potential to provide a cost-effective treatment option for patients with chronic back pain that will delay or possibly prevent the need for more invasive treatments such as surgery for spinal fusion or disc replacement.
SpineOvations is a San Diego-based, privately held medical device company focused on the development of novel, biocompatible injectables for the stabilization of spinal disc integrity and for other orthopedic applications including non-surgical connective tissue repair. The company’s technology platform consists of a novel non-surgical application for identifying and treating spinal discs that have tears or fissures in order to seal the defect and improve structural integrity.
SpineOvation’s DiscSeal™ is a percutaneous injection treatment for patients with Internal Disc Derangement (IDD) and suffering from chronic, discogenic lower back pain. DiscSeal is designed to be an early-stage treatment for those patients who have failed conservative care and who are not yet candidates for the invasive surgical treatment options of total disc replacement or spinal fusion, the largest segment of the spine market. For more information, visit: http://www.spineovations.com/
Source: SpineOvations
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.